| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Barron's Jumps On Gilead's Bandwagon
Posted on 11/02/2007 10:47:54 | Link | Post Comment
by Brett Scott
Sizz's Biotech Blog
Barron's July 9 issue was bullish on Gilead (GILD), saying that the stock could "climb another 20 to 25% (this year), fueled by strong demand for both existing drugs and remedies now in the pipeline." Barron's also stated that earnings could reach $2 per share by 2009.
This should be music to investors' ears. What should be even more encouraging to investors is the position that Gilead is in. The Barron's article outlines Gilead's successes, which start obviously with HIV. The article states that about 70% of new Atripla patients are switchovers from Glaxo's Combivir and other drugs. That's great for Gilead as it squashes some of the idea that Atripla was going to cannibalize sales of its other HIV drugs.
Furthermore, Tamiflu is being stockpiled by many countries and international agencies in case of a flu pandemic. This should help growth continue, as Tamiflu royalties account for about 20% of Gilead's revenues. Also, I see this as a great benefit because it keeps the company diversified.
The company will also be further diversified going forward with the approval of Letaris. Barron's states that the market for pulmonary arterial hypertension is $2 billion. The acquisition of Myogen, which created Letaris, and Corus Pharma have put Gilead in great position according to Barron's. Lastly, Barron's says that the company could be looking to make more acquisitions with over $2 billion in cash on hand or even be a takeover target itself.
This article could be what Gilead investors needed to get the stock out of its summer hibernation.
Disclosure: I am long shares of Gilead
RELATED READING:
- Gilead Q4 Report: Preview of Great Things to Come
- Gilead Submits New Drug Application to the FDA
- Gilead Sciences Acquires Myogen
Sizz's Biotech Blog is a regular contributor to BioHealth Investor
__________
Sizz's Biotech Blog
Barron's July 9 issue was bullish on Gilead (GILD), saying that the stock could "climb another 20 to 25% (this year), fueled by strong demand for both existing drugs and remedies now in the pipeline." Barron's also stated that earnings could reach $2 per share by 2009.
This should be music to investors' ears. What should be even more encouraging to investors is the position that Gilead is in. The Barron's article outlines Gilead's successes, which start obviously with HIV. The article states that about 70% of new Atripla patients are switchovers from Glaxo's Combivir and other drugs. That's great for Gilead as it squashes some of the idea that Atripla was going to cannibalize sales of its other HIV drugs.
Furthermore, Tamiflu is being stockpiled by many countries and international agencies in case of a flu pandemic. This should help growth continue, as Tamiflu royalties account for about 20% of Gilead's revenues. Also, I see this as a great benefit because it keeps the company diversified.
The company will also be further diversified going forward with the approval of Letaris. Barron's states that the market for pulmonary arterial hypertension is $2 billion. The acquisition of Myogen, which created Letaris, and Corus Pharma have put Gilead in great position according to Barron's. Lastly, Barron's says that the company could be looking to make more acquisitions with over $2 billion in cash on hand or even be a takeover target itself.
This article could be what Gilead investors needed to get the stock out of its summer hibernation.
Disclosure: I am long shares of Gilead
RELATED READING:
- Gilead Q4 Report: Preview of Great Things to Come
- Gilead Submits New Drug Application to the FDA
- Gilead Sciences Acquires Myogen
Sizz's Biotech Blog is a regular contributor to BioHealth Investor
__________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Ludwig von Mises Institute
- Credit Bloggers
- Millionaire Now! by Larry Nusbaum
- Don't Mess With Taxes
- Poor and Stupid
Examples
Morpheus Trading - Sun Aug 24, 2008 06:22AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Thu Aug 28, 2008 02:39AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Boucher On The Big Picture - Thu Aug 28, 2008 05:01PM
Market Needs to Show Volume and Breadth To Signal Next M [read more]
Market Needs to Show Volume and Breadth To Signal Next M [read more]
<< My Home | TheMoneyBlogs Home